Bone marrow immune cells and glioma progression in teens and young adults
Official title: Bone marrow-derived myeloid cell dysregulation in malignant progression of glioma
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11576103 · Data updated 2026-11-12
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 15, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $486,234 |
| NIH project number | 7R01NS127984-04 |
| Project ID | NIH-11576103 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants are adolescents and young adults with low-grade gliomas or related conditions who could contribute tumor or blood samples and may be candidates for future therapies.
✕Less likely to help
Some patients may not directly benefit if their tumor biology does not involve the studied immune pathways or if their disease is already advanced.
What this research studies
This project explores why some brain tumors in teens and young adults become more dangerous over time by studying bone marrow–derived immune cells and their interaction with brain tumors. Researchers will examine how these immune cells, including CD8+ T cells and other myeloid cells, are present in tumors and blood and how their activity might allow tumors to become more aggressive. The study plans experiments in models that mimic glioma progression and will test how a protein called ID2 affects these immune cells’ development. If successful, the work could reveal targets to support anti-tumor immunity and slow malignant transformation.
Why it matters
Potential benefit: If successful, this work could identify new ways to preserve anti-tumor immune responses and potentially slow or prevent progression of gliomas in young patients.
How similar studies have gone: Previous research has shown immune cells are linked to glioma progression, supporting the relevance of this immune-focused approach.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Rajappa, Prajwal — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Rajappa, Prajwal
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
-
Synergistic blood-brain barrier opening and targeted glioma treatment with pulsed electric fields
A new approach uses tiny, rapid electric pulses to safely disrupt the brain's protective barrier and enhance targeted treatment for malignant glioma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.